News

Designed to assess ascending doses of AHRO-001 in healthy adult volunteers, the randomized, double-blind study is being conducted in Russia with AtheroNova’s licensing partner, OOO CardioNova. The safety,

The patent expires in 2028 and covers methods of inhibiting inflammation by means of intravenous immunoglobulin (IVIG)-derived, sialylated Fc regions. Momenta president and chief executive officer Craig Wheeler

Itonis Pharmaceuticals head and the Zicam cold remedy inventor Dr Charles Hensley said that a labeler status is granted to the company that manufactures, repacks or distributes a

The open-label Phase I study is designed to assess the safety, tolerability and pharmacokinetics of MORAb-066 administered with weekly intravenous infusions. Morphotek president and CEO Nicholas Nicolaides said,

Expected to be available in Canada in the third quarter of 2013, Fibristal becomes the first approved medication to reduce fibroid size in addition to controlling symptoms. Actavis

Bayer HealthCare executive committee member and global drug discovery head Prof. Andreas Busch said, "Antibody-drug conjugates are promising approaches in oncology which can attack tumor cells in a

Under the terms of the agreement, Cytokinetics has given rights to Astellas to co-develop and commercialize CK-2127107, a fast skeletal troponin activator drug candidate, for potential application in

BAL30072 is developed to treat severe infections, including nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria. According to the terms of the contract, BARDA will provide nearly $17m of

The collaboration aims to identify preclinical assets against novel targets representing first-in-class opportunities, while Alacrita will support Debiopharm in search for small molecules, antibody or peptide-based product candidates.